Sanofi and Regeneron's Praluent achieves positive results in 'bad cholesterol'

1 September 2015

French drug major Sanofi (Euronext: SAN) and US biotech company Regeneron (Nasdaq: REGN) have announced that their Praluent (alirocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C), often referred to as “bad cholesterol.”

This was based on heterozygous familial hyperchlolesterolemia (HeFH) patients in the ODYSSEY clinical trial program, and the analysis of 1,257 is the largest group of HeFH patients ever studied in a Phase III program.

At week 24, patients treated with Praluent had an average 56% greater reduction in LDL-C compared to placebo in both arms, with reductions observed as early as wekk 4 and maintained for the duration of therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK